Literature DB >> 100812

Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid).

B Meldrum, R Horton.   

Abstract

The anticonvulsant potency and neurological toxicity of two new catalytic inhibitors of GABA-transaminase have been assessed in acute experiments in baboons with a natural syndrome of photic epilepsy. gamma-Acetylenic GABA, 160--200 mg/kg, or gamma-vinyl GABA, 450--950 mg/kg, intravenously, gave complete protection against generalised myoclonus or seizure responses induced by photic stimulation (in baboons without or with priming with subconvulsant doses of allylglycine). The protection became maximal 1--3 h after injection, and continued for 7--24 h. Signs characteristic of the acute toxicity of anticonvulsant drugs (nystagmus and ataxia) were not seen. The potential use of these compounds in human epilepsy deserves investigation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100812     DOI: 10.1007/bf00428029

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Catalytic inhibition of gamma-aminobutyric acid - alpha-ketoglutarate transaminase of bacterial origin by 4-aminohex-5-ynoic acid, a substrate analog.

Authors:  M J Jung; B W Metcalf
Journal:  Biochem Biophys Res Commun       Date:  1975-11-03       Impact factor: 3.575

Review 2.  Epilepsy and gamma-aminobutyric acid-mediated inhibition.

Authors:  B S Meldrum
Journal:  Int Rev Neurobiol       Date:  1975       Impact factor: 3.230

3.  The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gammma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo.

Authors:  M J Jung; B Lippert; B W Metcalf; P J Schechter; P Böhlen; A Sjoerdsma
Journal:  J Neurochem       Date:  1977-04       Impact factor: 5.372

4.  Effect of sodium n-dipropylacetate on audiogenic seizures and brain -aminobutyric acid level.

Authors:  S Simler; L Ciesielski; M Maitre; H Randrianarisoa; P Mandel
Journal:  Biochem Pharmacol       Date:  1973-07-15       Impact factor: 5.858

5.  Regional changes in cerebral GABA concentration and convulsions produced by D and by L-allylglycine.

Authors:  R W Horton; A G Chapman; B S Meldrum
Journal:  J Neurochem       Date:  1978-06       Impact factor: 5.372

6.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

7.  Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures.

Authors:  G Anlezark; R W Horton; B S Meldrium; C B Sawaya
Journal:  Biochem Pharmacol       Date:  1976-02-15       Impact factor: 5.858

8.  Effects of atropine and eserine on the electroencephalogram, on behaviour and on light-induced epilepsy in the adolescent baboon (Papio papio).

Authors:  B S Meldrum; R Naquet; E Balzano
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1970-05

9.  gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Authors:  M J Jung; B Lippert; B W Metcalf; P Böhlen; P J Schechter
Journal:  J Neurochem       Date:  1977-11       Impact factor: 5.372

10.  Seizures induced by allylglycine, 3-mercaptopropionic acid and 4-deoxypyridoxine in mice and photosensitive baboons, and different modes of inhibition of cerebral glutamic acid decarboxylase.

Authors:  R W Horton; B S Meldrum
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

View more
  11 in total

Review 1.  The role of the brain stem in generalized epileptic seizures.

Authors:  C L Faingold
Journal:  Metab Brain Dis       Date:  1987-06       Impact factor: 3.584

Review 2.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 4.  GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

Authors:  B S Meldrum
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

5.  Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice.

Authors:  R Bernasconi; M Klein; P Martin; P Christen; T Hafner; C Portet; M Schmutz
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 6.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

7.  Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients.

Authors:  A Pitkänen; R Matilainen; T Ruutiainen; M Lehtinen; P Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

Review 8.  Place of newer antiepileptic drugs in the treatment of epilepsy.

Authors:  R Kälviäinen; T Keränen; P J Riekkinen
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

9.  Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina.

Authors:  M J Neal; M A Shah
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

10.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo.

Authors:  D L Rothman; O A Petroff; K L Behar; R H Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.